

Diaxonhit wins a major public tender from the Paris Hospitals (Assistance Publique – Hôpitaux de Paris)

Diaxonhit confirms its leading position in France in the field of transplantation

Paris, France – April 23, 2013 – Diaxonhit, the leading French provider of specialty diagnostic solutions, won through its marketing subsidiary InGen, a major tender from the AGEPS, the Paris Hospitals' (Assistance Publique - Hôpitaux de Paris, AP-HP) central purchasing agency. It involves the supply of tests necessary to perform histocompatibility studies in the context of transplantation activities. The tender covers the next two years and represents potential revenues of up to € 5.5 million per year.

«After our successful bid to the French Blood Bank in February, AP-HP - the largest university hospital in Europe and a key player in transplantation in France - also renewed its confidence in our company by extending for two more years the existing supplier relationship. This new contract confirms our leading position in the field of transplantation»
said Loïc Maurel, CEO of Diaxonhit.

Histocompatibility studies: a key to successful transplantations

Histocompatibility studies are necessary to assess compatibility between donors and recipients before transplantation, and to follow-up patients after transplantation in order to monitor potential rejections and to adjust immunosuppressive treatments accordingly.

The field of transplantation covers activities related to organ and bone marrow transplantation. In 2011, 4,954 transplants were carried out in France, with an additional 16,371 patients awaiting transplantation ⁽¹⁾. This number increases by about 4% per year ⁽²⁾. Rejection is the main risk related to transplantation, the rate of acute rejection at one year after transplant ranging between 5% (kidney) and 50% (lung)⁽²⁾.

Diaxonhit: leader in France for tests related to transplantation

The markets that are accessed by InGen, Diaxonhit's marketing subsidiary, include the supply of tests for HLA⁽³⁾ typing and tests for detection and identification of anti-HLA antibodies to specialized AP-HP laboratories.

Diaxonhit is currently the leading supplier of HLA laboratories, with over 70% market share in the French territory. Its partner is One Lambda (USA), the world leader for HLA tests and part of Thermo Fisher Scientific since mid-2012.

(1) Source : French Biomedicine Agency, www.dondorganes.fr/016-les-chiffres-cles

(2) Source : Inserm, www.inserm.fr/thematiques/sante-publique/dossiers-d-information/transplantation-d-organes

(3) Human Leucocyte Antigen

About Diaxonhit

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in the in-vitro diagnostic field, involved from research to commercialization of specialty diagnostic products.

With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in-vitro diagnostic kits and advanced equipment. It operates mainly in the fields of transplantation, infectious diseases and autoimmunity, product quality control and rapid tests, including Tetanus Quick Stick ®, a proprietary product.

The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering three main specialty areas: immuno-infection, Alzheimer's disease and cancer.

Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index.

For more information, please visit: <http://www.diaxonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, Exonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

CONTACTS

DIAXONHIT

Hervé Duchesne de Lamotte
CFO
+33 1 53 94 52 49
herve.delamotte@diaxonhit.com

ACTIFIN

Financial Communication
+ 33 1 56 88 11 11
Investors Relations
Alexandre Commerot, acommerot@actifin.fr
Press Relations
Jennifer Jullia, jjullia@actifin.fr